Table of Content PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Autoimmune and inflammatory diseases • Rheumatoid arthritis • IBD • Top immunomodulators for rheumatoid arthritis and IBD PART 06: Pipeline portfolio PART 07: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 08: Market segmentation by type of disease • Global rheumatoid arthritis immunomodulators market • Global IBD immunomodulators market PART 09: Market segmentation by molecule type • Global autoimmune and inflammatory biologic immunomodulators market • Global autoimmune and inflammatory small molecule immunomodulators market PART 10: Geographical segmentation • Global autoimmune and inflammatory immunomodulators market by geography 2015-2020 • Autoimmune and inflammatory immunomodulators market in Americas • Autoimmune and inflammatory immunomodulators market in EMEA • Autoimmune and inflammatory immunomodulators market in APAC PART 11: Market drivers • Strong adoption of TNF-alpha inhibitors and B-cell inhibitors • Development of novel therapies using innovative technologies • Improved diagnostic tools increase the treatment-seeking population PART 12: Impact of drivers PART 13: Market challenges • Discontinuation of drugs under development leading to substantial loss of revenue • Growing popularity of alternative treatment procedures hinders the market growth • Adverse effects of the drugs PART 14: Impact of drivers and challenges PART 15: Market trends • Emergence of oral agents likely to improve patient outcomes • Advent of biosimilars expected to improve the treatment rates • Focus on regenerative medicines • Strategic alliances and acquisitions PART 16: Vendor landscape • Competitive scenario • Other prominent vendors PART 17: Key vendor analysis • AbbVie • Johnson & Johnson • Amgen • F. Hoffmann-La Roche • Pfizer PART 18: Appendix • List of abbreviations PART 19: Explore Technavio   List of Exhibits Exhibit 01: Product offerings Exhibit 02: Different classes of immunosuppressant drugs based on their mechanism of action Exhibit 03: Key buying criteria for global autoimmune and inflammatory immunomodulators market 2015 Exhibit 04: Key customer segments of autoimmune and inflammatory immunomodulators market Exhibit 05: Etiology of autoimmune diseases Exhibit 06: Pipeline portfolio: Rheumatoid arthritis immunomodulators Exhibit 07: Pipeline portfolio: Ulcerative colitis immunomodulators Exhibit 08: Pipeline portfolio: Crohn's disease immunomodulators Exhibit 09: Global autoimmune and inflammatory immunomodulators market snapshot: Developed and emerging markets 2015 Exhibit 10: Factors influencing global autoimmune and inflammatory immunomodulators market Exhibit 11: Approval and patent expiries of top-selling biologics Exhibit 12: Impact of factors affecting the market 2015 and 2020 Exhibit 13: Global autoimmune and inflammatory immunomodulators market 2015-2020 ($ billions) Exhibit 14: Five forces analysis Exhibit 15: Segmentation of global autoimmune and inflammatory immunomodulators by type of disease based on revenue 2015 Exhibit 16: Global autoimmune and inflammatory immunomodulators market by disease type 2015-2020 Exhibit 17: Global rheumatoid arthritis immunomodulators market 2015-2020 ($ billions) Exhibit 18: Opportunities across rheumatoid arthritis industry Exhibit 19: Global IBD immunomodulators market 2015-2020 ($ billions) Exhibit 20: Global IBD therapeutics market segmentation growth lifecycle analysis Exhibit 21: Global IBD immunomodulators market by disease type 2015-2020 Exhibit 22: Global ulcerative colitis immunomodulators market 2015-2020 ($ billions) Exhibit 23: Global Crohn's disease immunomodulators market 2015-2020 ($ billions) Exhibit 24: Comparative graph of global autoimmune and inflammatory immunomodulators market by molecule type ($ billions) Exhibit 25: Global autoimmune and inflammatory biologic immunomodulators market 2015-2020 ($ billions) Exhibit 26: Biologicals approvals by the US FDA Exhibit 27: Global rheumatoid arthritis biologic immunomodulators market 2015-2020 ($ billions) Exhibit 28: Global IBD biologic immunomodulators market 2015-2020 ($ billions) Exhibit 29: Global autoimmune and inflammatory small molecule immunomodulators market 2015-2020 ($ billions) Exhibit 30: Global autoimmune and inflammatory immunomodulators market by geography 2015-2020 Exhibit 31: Global autoimmune and inflammatory immunomodulators market segmentation by geography 2015-2020 ($ billions) Exhibit 32: Global share of autoimmune and inflammatory immunomodulators market by geography 2015 Exhibit 33: Global autoimmune and inflammatory immunomodulators market segmentation by region: Market growth lifecycle analysis 2015 Exhibit 34: Global autoimmune and inflammatory immunomodulators market: Country analysis based on revenue and growth rate Exhibit 35: Opportunity analysis of autoimmune and inflammatory immunomodulators market in Americas Exhibit 36: Autoimmune and inflammatory immunomodulators market in Americas 2015-2020 ($ billions) Exhibit 37: Opportunity analysis of autoimmune and inflammatory immunomodulators market in EMEA Exhibit 38: Autoimmune and inflammatory immunomodulators market in EMEA 2015-2020 ($ billions) Exhibit 39: Opportunity analysis of autoimmune and inflammatory immunomodulators market in APAC Exhibit 40: Autoimmune and inflammatory immunomodulators market in APAC 2015-2020 ($ billions) Exhibit 41: Sales performance of key TNF-alpha inhibitors and B-cell inhibitors ($ billions) Exhibit 42: Key vendors: Developing novel therapies Exhibit 43: Key developments leading to improved diagnostics Exhibit 44: Impact of drivers Exhibit 45: List of few immunomodulators that were discontinued from development or market Exhibit 46: CAM therapies for rheumatoid arthritis Exhibit 47: Usage of CAM therapies in US adults Exhibit 48: List of CAM therapies and items used in Crohn's disease and ulcerative colitis Exhibit 49: List of adverse side effects associated with rheumatoid arthritis Exhibit 50: Impact of drivers and challenges Exhibit 51: Key marketed and pipeline oral agents Exhibit 52: List of few biosimilars under development for various indications Exhibit 53: List of few regenerative medicines under development for rheumatoid arthritis and IBD Exhibit 54: Key deals in global immunomodulators market Exhibit 55: Market share of key vendors 2015 Exhibit 56: Geographical presence of key vendors Exhibit 57: Competitive scenario of global autoimmune and inflammatory immunomodulators market vendors 2015-2020 Exhibit 58: AbbVie: Strength assessment Exhibit 59: AbbVie: Strategy assessment Exhibit 60: AbbVie: Opportunity assessment Exhibit 61: AbbVie: YoY growth and revenue of Humira 2013-2015 ($ billions) Exhibit 62: Johnson & Johnson: Strength assessment Exhibit 63: Johnson & Johnson: Strategy assessment Exhibit 64: Johnson & Johnson: Opportunity assessment Exhibit 65: Johnson & Johnson: YoY revenue and growth rate of Remicade 2013-2015 ($ billions) Exhibit 66: Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria 2013-2015 ($ billions) Exhibit 67: Amgen: Strength assessment Exhibit 68: Amgen: Strategy assessment Exhibit 69: Amgen: Opportunity assessment Exhibit 70: Amgen: YoY revenue and growth rate of Enbrel (in the US and Canada) 2013-2015 ($ billions) Exhibit 71: F. Hoffmann-La Roche: Strength assessment Exhibit 72: F. Hoffmann-La Roche: Strategy assessment Exhibit 73: F. Hoffmann-La Roche: Opportunity assessment Exhibit 74: F. Hoffmann-La Roche: YoY growth and revenue of MabThera/Rituxan for immunology segment 2013-2015 ($ billions) Exhibit 75: F. Hoffmann-La Roche: YoY growth and revenue of Actemra/RoActemra for immunology segment 2013-2015 ($ billions) Exhibit 76: Pfizer: Strength assessment Exhibit 78: Pfizer: Strategy assessment Exhibit 79: Pfizer: Opportunity assessment Exhibit 80: Pfizer: Global autoimmune and inflammatory immunomodulators revenues 2014-2015 ($ billions)

AbbVie, Johnson & Johnson, Amgen, F. Hoffmann-La Roche, Pfizer, AstraZeneca, Avaxia Biologics, Biogen Idec, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Enlivex Therapeutics, Gilead Sciences, Immune Pharmaceuticals, Merck, Mitsubishi Tanabe Pharma, Neovacs, Prometheus Laboratories, Sandoz, Sanofi, Swedish Orphan Biovitrum, Takeda Pharmaceuticals, UCB.